Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VRAYLAR vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Schizophrenia,Acute treatment of manic or mixed episodes associated with bipolar I disorder,Depressive episodes associated with bipolar I disorder (bipolar depression)
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
The terminal elimination half-life of cariprazine is 2-4 days, and for its active metabolites (desmethylcariprazine and didesmethylcariprazine) it is 1-3 weeks. This long half-life results in steady-state concentrations being reached after 3-4 weeks of daily dosing, contributing to prolonged clinical effects and a need for slow titration.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Active metabolites include didesmethylcariprazine (DDCAR) and desmethylcariprazine (DCAR).
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Cariprazine and its active metabolites are primarily eliminated via hepatic metabolism and subsequent biliary/fecal excretion. Approximately 20% of the dose is recovered in urine, mainly as inactive metabolites, while about 80% is recovered in feces, largely as unchanged cariprazine and its active metabolites.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Cariprazine is 91-97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
>99% bound to albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution (Vd/F) is approximately 8.3 L/kg, indicating extensive tissue distribution and high lipophilicity.
4.9 L/kg (high distribution into tissues).
Absolute oral bioavailability is not determined; however, after oral administration, peak plasma concentrations occur within 3-6 hours. Food does not significantly affect the extent of absorption.
Oral: 87% (tablet and solution); IM: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1.5 mg daily; maximum 3 mg/day. Child-Pugh Class C: Not recommended.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Safety and efficacy not established in pediatric patients under 18 years; not recommended.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Elderly patients may have lower clearance; use lowest effective dose (1.5 mg daily) and titrate slowly. Not approved for dementia-related psychosis due to increased mortality risk.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse reactions in elderly patients with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Leukopenia, neutropenia, and agranulocytosis,Orthostatic hypotension and syncope,Falls,Seizures,Body temperature dysregulation,Dysphagia,Cognitive and motor impairment
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Known hypersensitivity to cariprazine or any components of the formulation
Known hypersensitivity to aripiprazole or any of its excipients.
No specific food restrictions. Vraylar can be taken with or without food. Grapefruit and grapefruit juice do not significantly interact with Vraylar. High-fat meals do not affect absorption.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following late third trimester exposure. Vraylar (cariprazine) is classified as Pregnancy Category C; no adequate human studies.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Excretion into human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, discontinue drug or nursing, considering importance of drug to mother.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
No established dosing adjustments for pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure. Use lowest effective dose and monitor clinical response and tolerability. Clinical pharmacokinetic data not available; consider empiric dose adjustment based on tolerability.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Vraylar (cariprazine) requires dose adjustment in moderate hepatic impairment (Child-Pugh B): maximum dose 3 mg/day. Avoid in severe hepatic impairment (Child-Pugh C). Titrate slowly to minimize akathisia risk. For acute mania, start at 1.5 mg/day on day 1, increase to 3 mg/day on day 2. For schizophrenia, start at 1.5 mg/day, may increase to 3 mg/day after 2 days, then further in 1.5 mg increments weekly. For bipolar depression, target dose is 1.5-3 mg/day; start at 1.5 mg/day, increase to 3 mg/day after 2 days if needed. Monitor for extrapyramidal symptoms, especially akathisia which is dose-dependent. Renal impairment: no dose adjustment needed. CYP3A4 inducers (e.g., rifampin) decrease exposure; may need dose increase. CYP3A4 inhibitors (e.g., ketoconazole) increase exposure; reduce dose.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
Take Vraylar once daily with or without food. Swallow capsules whole; do not crush or chew.,Do not abruptly stop taking Vraylar without talking to your doctor; sudden discontinuation may cause withdrawal symptoms such as nausea, vomiting, or trouble sleeping.,Avoid alcohol and illicit drugs while taking Vraylar, as they can worsen side effects like dizziness or drowsiness.,You may experience restlessness or an urge to move (akathisia), especially during dose increases; tell your doctor if this occurs.,Vraylar may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how the medication affects you.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double up.,Contact your doctor immediately if you experience uncontrolled muscle movements, especially of the face or tongue, or signs of neuroleptic malignant syndrome (fever, muscle rigidity, confusion).,Store at room temperature 20-25°C (68-77°F), away from moisture and heat.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VRAYLAR vs ABILIFY, answered by our medical review team.
VRAYLAR is a Atypical Antipsychotic that works by Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VRAYLAR and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VRAYLAR is: 1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VRAYLAR and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VRAYLAR is classified as Category C. First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following l. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.